Top in rheumatology: Adalimumab biosimilar approval; the immunopathophysiology of PsA
Click Here to Manage Email Alerts
The FDA approved Idacio as a biosimilar to Humira, a TNF inhibitor with indications for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis and plaque psoriasis.
According to the manufacturer, Idacio (adalimumab-aacf, Fresenius Kabi) is a citrate-free formulation of Humira (adalimumab, AbbVie). It was the top story in rheumatology last week.
The second top story explored the mechanism of action by which psoriatic arthritis treatment works.
Read these and more top stories in rheumatology below:
FDA approves Fresenius Kabi’s Idacio as eighth adalimumab biosimilar
The FDA has approved Idacio as the eighth biosimilar to adalimumab, for all eligible indications of the reference product, clearing the way for its U.S. release in 2023 alongside a deluge of other Humira biosimilars. Read more.
Understanding the immunopathophysiology of PsA
Understanding the mechanism of action by which psoriatic arthritis treatment works and taking a patient’s lifestyle into account can benefit clinicians treating patients with the condition, said Philip J. Mease, MD, of the Swedish Medical Center in Seattle and the University of Washington. Read more.
Patients with IMIDs, myocardial infarction at higher risk for death, heart failure
Patients with rheumatic immune-mediated inflammatory disease who experience myocardial infarction are more likely to die or experience heart failure vs. patients without immune-mediated inflammatory disease, according to data. Read more.
Cigna Pharmacy to list adalimumab biosimilars at same price point as originator
Cigna Pharmacy announced that it will add adalimumab biosimilars as “preferred products” at the same price level as the originator Humira on its commercial formularies, according to a company press release. Read more.
Lorecivivint delays osteoarthritis structural progression in long-term extension study
Repeat injections of the Wnt pathway inhibitor lorecivivint (SM04690, Biosplice) appears to have slowed the decline of medial joint space width in knee osteoarthritis, according to interim results from a long-term extension trial released by Biosplice. Read more.